CEO Eric Bernard sees Sonova leading the race against Demant and is betting on a new platform and Asia. Growth in cochlear implants, however, now clearly depends on FDA approval.
✦ The floor
Discussion
Signed responses from readers of the wire.
No actionable change — this is a corporate strategy interview with no clinical evidence or guidance implications for practicing audiologists.
Sonova's declared AI platform investment and Asia expansion signal a likely acceleration in AI-driven hearing aid features and increased global market competition, which could shape product availability and pricing for clinics worldwide.
- 01Sonova CEO Eric Bernard signals intent to outgrow Demant via a new AI platform and Asia-Pacific expansion.
- 02Cochlear implant growth is explicitly tied to pending FDA regulatory approval.
- 03AI integration is positioned as a core competitive differentiator against rival manufacturers.
- 04Asia is identified as a key untapped market for hearing technology growth.
- 05The statement 'we will continue to take share' reflects a confident, competitive posture — not confirmed market data.
Sonova will continue to take market share from competitors, including Demant.
quoteunclearSonova's cochlear implant growth depends on FDA approval.
quotesupportedA new AI platform will help Sonova outpace Demant.
quotepromotional